4D molecular therapeutics CEO Kirn sells $811,003 in stock

David Kirn, CEO of 4D Molecular Therapeutics, sold 58,333 shares of the company's stock on September 14, 2026. The transaction totaled $811,003, with shares sold at an average price of $13.903, between $13.43 and $14.15 per share. The sale adhered to a pre-arranged 10b5-1 trading plan Kirn put in place on January 9, 2026. The stock had recently shown strong performance, with a 106% return over the past year and a 62% gain in the last six months, according to InvestingPro analysis.

FDMT's current market cap is $758 million, and analysts believe the stock is undervalued compared to its fair value. After the sale, Kirn personally owns 767,486 shares of the company's common stock. 4D Molecular Therapeutics has recently gained attention for various developments. Cantor Fitzgerald upgraded the company's rating to Overweight, predicting a potential price of $20, citing strong gene therapy prospects, particularly the intravitreal VEGF gene therapy, 4D-150.

H.C. Wainwright maintained a Buy rating with a $36 price target following promising Phase 2b trial data and positive progress in Phase 3 trials. B. Riley also initiated coverage with a Buy rating and a $37 price target, highlighting the potential of 4D-150 in the 4FRONT Phase 3 studies. These developments reflect growing confidence in 4D Molecular Therapeutics' innovative gene therapy solutions, particularly the trials for the neovascular AMD treatment, 4D-150.